(129 days)
No
The document describes a neuromodulation device that delivers electrical signals for pain relief. There is no mention of AI, ML, or any related concepts in the device description, intended use, or performance studies. The testing focuses on electrical and operational safety and functionality.
Yes
The device is clearly described as a "Pain Therapy Device" intended for "symptomatic relief of chronic, intractable pain," "acute pain," and "post-surgical and post-traumatic acute pain," which are all therapeutic indications.
No
Explanation: The device is described as a "Pain Therapy Device" intended for symptomatic relief of pain, not for diagnosing medical conditions. Its function is to deliver electrical signals for pain relief, not to identify or characterize disease states.
No
The device description explicitly states it is a "battery-powered device" and mentions testing of hardware components like the battery, cable, electrodes, and charger ports. This indicates it is a physical device with embedded software, not a software-only medical device.
Based on the provided information, the BioWaveGO Neuromodulation Pain Therapy Device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood, urine, or tissue, to detect diseases, conditions, or infections.
- BioWaveGO Function: The description clearly states that the BioWaveGO is a "battery-powered device intended to provide pain the technology of parent devices BioWavePRO." It delivers electrical signals through electrodes applied to the body for pain relief.
- No Sample Analysis: There is no mention of the device analyzing any biological samples from the patient. Its function is based on delivering electrical stimulation directly to the body.
Therefore, the BioWaveGO falls under the category of a therapeutic device, specifically a neuromodulation device for pain management, rather than an in vitro diagnostic device.
N/A
Intended Use / Indications for Use
The BioWaveGO Neuromodulation Pain Therapy Device is indicated for:
- Symptomatic relief of chronic, intractable pain
- Symptomatic relief of acute pain
- As an adjunctive treatment in the management of post-surgical and post-traumatic acute pain
Product codes
NUH, GZJ
Device Description
The BioWaveGO Neuromodulation Pain Therapy Device is a battery-powered device intended to provide pain the technology of parent devices BioWavePRO. The key difference between the BioWaveGO and the parent device, the BioWaveHOME, is a reduced maximum voltage level, making the device available over-the-counter. The BioWaveGO device has a smaller battery system compared to the BioWaveGO device delivers the summed high frequency alternating current sinusoidal signals between electrodes, providing symptomatic relief of acute, chronic, and post-operative pain.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
The testing of the BioWaveGO device and the smartphone app includes:
- Testing of basic operational modes to confirm that the session timer is only operational during active treatment time.
- Battery testing to ensure charging only occurs when the device is not in use and that active treatment sessions cannot be started during charging.
- Testing to ensure consistent operation across various intensities and load impedances.
- Testing to ensure recognition of the cable and electrodes before and during an active session.
- Testing to ensure invalid load impendences are detected before and during an active session.
- Abuse of the battery charger input and output ports testing to determine if damage to the device or improper software operation occurs.
- Testing in over-temperature situations to determine if the inherent protect draw on the battery outside safe operating temperatures.
- Testing to determine if the hardware watchdog timers were functional at resetting the device.
- Evaluation of electrical safety.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 882.5890 Transcutaneous electrical nerve stimulator for pain relief.
(a)
Identification. A transcutaneous electrical nerve stimulator for pain relief is a device used to apply an electrical current to electrodes on a patient's skin to treat pain.(b)
Classification. Class II (performance standards).
0
Image /page/0/Picture/0 description: The image shows the date August 17, 2018. The text is in a simple, sans-serif font and is horizontally aligned. The date is written out in full, with the month, day, and year clearly visible.
Biowave Corporation % Dave Mcgurl Director, Spine Regulatory Affairs Musculoskeletal Clinical Regulatory Advisers, LLC (MCRA) 1050 K Street NW. Suite 1000 Washington, District of Columbia 20001
Re: K180943
Trade/Device Name: BioWaveGO Regulation Number: 21 CFR 882.5890 Regulation Name: Transcutaneous Electrical Nerve Stimulator For Pain Relief Regulatory Class: Class II Product Code: NUH, GZJ Dated: July 11, 2018 Received: July 11, 2018
Dear Dave McGurl:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820);
1
and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Carlos L. Pena -S) A
Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K180943
Device Name BioWaveGo
Indications for Use (Describe)
The BioWaveGO Neuromodulation Pain Therapy Device is indicated for:
-
Symptomatic relief of chronic, intractable pain
-
Symptomatic relief of acute pain
-
As an adjunctive treatment in the management of post-surgical and post-traumatic acute pain
Prescription Use (Part 21 CFR 801 Subpart D)
X Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
3
510(K) SUMMARY
K180943
| Device Trade Name: | BioWaveGO System |
|---|---|
| Manufacturer: | BioWave Corporation |
| 8 Knight Street, Suite 201 | |
| Norwalk, CT 06851 | |
| Contact: | Bradford Siff |
| Founder & President | |
| BioWave Corporation | |
| 8 Knight Street, Suite 201 | |
| Norwalk, CT 06851 | |
| Phone: 203-635-7175 | |
| Fax: 203-286-2518 | |
| brad.siff@biowave.com | |
| Prepared by: | Mr. Dave McGurl |
| Director, Regulatory Affairs | |
| Musculoskeletal Clinical Regulatory Advisers, LLC | |
| 1050 K Street NW, Suite 1000 | |
| Washington, DC 20001 | |
| Office: 202.552.5797 | |
| Fax: 202.552.5798 | |
| dmcgurl@mcra.com | |
| Date Prepared: | April 26th, 2018 |
| Classifications: | 21 CFR §882.5890, Transcutaneous electrical nerve stimulator for pain relief |
4
Class: II
Product Codes: NUH, GZJ
Indications For Use:
The BioWaveGO Neuromodulation Pain Therapy is indicated for:
- · Symptomatic relief of chronic, intractable pain
- Symptomatic relief of acute pain
- As an adjunctive treatment in the management of post-surgical and post-traumatic acute pain
Device Description:
The BioWaveGO Neuromodulation Pain Therapy Device is a battery-powered device intended to provide pain the technology of parent devices BioWavePRO. The key difference between the BioWaveGO and the parent device, the BioWaveHOME, is a reduced maximum voltage level, making the device available over-the-counter. The BioWaveGO device has a smaller battery system compared to the BioWaveGO device delivers the summed high frequency alternating current sinusoidal signals between electrodes, providing symptomatic relief of acute, chronic, and post-operative pain.
Predicate Device:
The Bio Wave Corporation's Bio WaveGO Neuromodulation Pain Therapy Device is substantially equivalent to the previously cleared with respect to indications, design, function, and materials, as outlined below.
| Manufacturer | Device Name | K-Number |
|---|---|---|
| BioWave Corporation | ||
| (primary predicate) | BioWaveHOME | K152437 |
| NeuroMetrix, Inc. | ||
| (reference device) | Quell | K152954 |
| Fuji Dynamics Ltd. | ||
| (reference device) | LL TENS 160A, LL TENS 160B | K152374 |
Performance Testing Summary:
The testing of the BioWaveGO device and the smartphone app includes:
5
- · Testing of basic operational modes to confirm that the session timer is only operational during active treatment time.
- · Battery testing to ensure charging only occurs when the device is not in use and that active treatment sessions cannot be started during charging.
- Testing to ensure consistent operation across various intensities and load impedances. .
- Testing to ensure recognition of the cable and electrodes before and during an active session. .
- Testing to ensure invalid load impendences are detected before and during an active session. ●
- Abuse of the battery charger input and output ports testing to determine if damage to the device or improper software operation occurs.
- · Testing in over-temperature situations to determine if the inherent protect draw on the battery outside safe operating temperatures.
- · Testing to determine if the hardware watchdog timers were functional at resetting the device.
- Evaluation of electrical safety. .
| Predicate Comparison Table | |||
|---|---|---|---|
| Subject Device | |||
| BioWaveGO Device | Predicate Device | ||
| BioWaveHOME Device | Reference Device | ||
| Quell | |||
| Manufacturer | BioWave Corporation | BioWave Corporation | Neurometrix, Inc. |
| Trade Name | BioWaveGO | BioWaveHOME | Quell |
| 510(k) | K180943 | K152437 | K152954 |
| Bluetooth Capable | Yes | No | Yes |
| Smartphone | |||
| Interface | Yes | No | Yes |
| Prescription or | |||
| Over-the-Counter | Over-the-Counter | Prescription | Over-the-Counter |
Substantial Equivalence:
6
| Subject Device | Predicate Device | Reference Device | |
|---|---|---|---|
| BioWaveGO Device | BioWaveHOME Device | Quell | |
| Image | Image: BioWaveGO Device | Image: BioWaveHOME Device | Image: Quell |
| Indications | The BioWaveGO Neuromodulation Pain | ||
| Therapy Device is indicated for: |
- Symptomatic relief of chronic,
intractable pain, post-surgical, and post-
traumatic acute pain - Symptomatic relief of acute pain
- Symptomatic relief of post-operative
pain | The BioWaveHOME Neuromodulation
Pain Therapy Device is indicated for: - Symptomatic relief of chronic,
intractable pain, post-surgical, and post-
traumatic acute pain - Symptomatic relief of acute pain
- Symptomatic relief of post-operative
pain | Quell is intended for use as a
transcutaneous electrical nerve
stimulation device for the symptomatic
relief and management of chronic
intractable pain.
The device may be used during sleep. The
device is labeled for use only with
compatible NeuroMetrix electrodes. |
| | BioWave Corporation
BioWaveGO Device | BioWave Corporation
BioWaveHOME Device | Comparison of BioWaveGO and
BioWaveHOME |
| 510(k) Number | K180943 | K152437 | - |
| Device Name, Model | BioWaveGO | BioWaveHOME | - |
| Manufacturer | BioWave Corporation | BioWave Corporation | Identical |
| Availability | Over-the-Counter | Prescription | BioWaveGO is designed as an over-the-
counter neuromodulation pain therapy device
sharing identical specifications to the parent
device, BioWaveHOME, with the exception
of a decreased maximum voltage (20V versus
27.5V) |
| Power Source(s) | one 3.2V 1100mAh rechargeable
lithium iron phosphate battery | two 3.2V 3300mAh rechargeable
lithium iron phosphate batteries | Similar power source but a smaller battery
system in BioWaveGO vs BioWaveHOME |
| Method of Line Current Isolation | Battery + interlocks | Battery + interlocks | Identical |
| Patient Leakage Current | None | None | Identical |
| Normal condition | None | None | Identical |
| Single fault condition | None | None | Identical |
| Number of Output Modes | One | One | Identical |
| Number of Output Channels | One | One | Identical |
| Synchronous or Alternating? | N/A | N/A | - |
| Method of Channel Isolation | N/A | N/A | - |
| Regulated Current or Regulated
Voltage? | Regulated Voltage | Regulated Voltage | Identical |
| Software/Firmware/Microprocessor
Control? | Yes | Yes | Identical |
| Automatic Overload Trip? | Yes (software) | Yes (software) | Identical |
| Automatic No-Load Trip? | Yes (software) | Yes (software) | Identical |
| Automatic Shut Off? | Yes | Yes | Identical |
| Patient Override Control? | Yes | Yes | Identical |
| Indicator Display: | Yes | Yes | Identical |
| On/Off Status? | Yes | Yes | Identical |
| Low Battery? | Yes | Yes | Identical |
| Voltage/Current Level? | Yes (% of full scale) | Yes (% of full scale) | Identical |
| Timer Range - (minutes) | 30 | 30 | Identical |
| Compliance with Voluntary
Standards? | Yes | Yes | Identical |
| | BioWave Corporation
BioWaveGO Device | BioWave Corporation
BioWaveHOME Device | Comparison of BioWaveGO and
BioWaveHOME |
| Compliance with 21 CFR 898? | Yes | Yes | Identical |
| Weight | 6 ounces | 1.0 lbs | BioWaveGO is lighter |
| Dimensions (in.) (W x H x D) | 3.0" x 4.0" x 1.0" | 3.75" x 6.0" x 1.75" | BioWaveGO is smaller |
| Housing Materials and Construction | ABS via conventional injection
molding | ABS via conventional injection
molding | Identical |
7
Comparison of Basic Unit Characteristics for BioWaveHOME and BioWaveGO
8
Comparison of Output Specifications for BioWaveHOME and BioWaveGO
| | BioWave Corporation
BioWaveGO Device | Parent BioWave Corporation
BioWaveHOME Device | Comparison of BioWaveGO and
BioWaveHOME |
|-----------------------------------------------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Waveform | Biphasic | Biphasic | Identical |
| Shape | Sum of 2 sine waves | Sum of 2 sine waves | Identical |
| Maximum Output Voltage
Available(+1-2%) (with software
calibration correction) | 80V p-p @ 500 Ω
20 V AC RMS | 110V p-p @ 500 Ω
27.5 V AC RMS | BioWaveGO offers a decreased maximum
voltage to allow for over-the-counter
availability. The decrease in voltage does not
impact safety or performance of the device. |
| Maximum Output Current(+1- 2 %)
(current depends on load) | 160mA p-p @ 500 Ω
40mA RMS
40 mA p-p @ 2kΩ
Trip out @ 10kΩ | 220mA p-p @ 500 Ω
55mA RMS
55 mA p-p @ 2kΩ
Trip out @ 10kΩ | BioWaveGO has a lower maximum current
density. |
| Pulse Width | Continuous modulation | Continuous modulation | Identical |
| For multiphasic waveforms only:
- Symmetrical phases?
- Phase Duration | N/A
N/A | N/A
N/A | - |
| Net Charge (m C per pulse) (If zero,
state method of achieving zero net
charge.) | 0 @ 500 Ω
biphasic – AC coupled continuous
wave | 0 @ 500 Ω
biphasic – AC coupled continuous
wave | Identical |
| Maximum Phase Charge, (μ C) | N/A | N/A | - |
| Maximum Current Density,
(µmA/cm²) (with 1.375" diam pad =
9.58 cm2 area) | 6.9 ma rms per cm² @ 500 Ω | 6.9 ma rms per cm² @ 500 Ω | Identical |
| Maximum Power Density, (W/cm²)
(using 1.375" diam 9.58 cm² electrode
conductive surface area) | 0.19 W rms per cm² @ 500 Ω | 0.19 W rms per cm² @ 500 Ω | Identical |
| Burst Mode
a. Pulses per burst
b. Bursts per second
c. Burst duration (seconds) | N/A | N/A | - |
9
| BioWave Corporation | Parent BioWave Corporation | Comparison of BioWaveGO and | |
|---|---|---|---|
| BioWaveGO Device | BioWaveHOME Device | BioWaveHOME | |
| d. Duty Cycle [Line (b) x Line (c)] | |||
| ON Time (seconds) | N/A | N/A | - |
| OFF Time (seconds) | N/A | N/A | - |
| Additional Features (if applicable) | Many safety interlocks: cable | ||
| connected to unit, pads connected to | |||
| cable, pads connected to body, max | |||
| power density, battery ok for | |||
| treatment, charger connected (trip | |||
| off) | Many safety interlocks: cable | ||
| connected to unit, pads connected to | |||
| cable, pads connected to body, max | |||
| power density, battery ok for | |||
| treatment, charger connected (trip | |||
| off) | Identical |
The subject device, the BioWaveGO, was demonstrated to be substantially equivalent to predicate device K152437 cited in the table above with respect to design, materials, function, manufacturing, and to the reference devices (K152374 and K152954) with respect to IFU and over-the-counter use.
Conclusion:
The BioWaveGO device has been found to be substantially equivalent to the previously cleared predicate device, BioWaveHOME (K152437), with respect to its design, function, materials, and the reference devices, LL TENS 160A, LL TENS 160B (K152374) and Quell (K152954) with respect to indications for use and over-the-counter availability.